论文部分内容阅读
用抗多药耐药Ｐ－糖蛋白（Ｐ－ｇｐ）及流式细胞仪间接免疫荧光法检测了１７３例初治、２３例难治成人急性髓细胞白血病（ＡＭＬ）细胞Ｐ－ｇｐ的表达。结果发现，Ｐ－ｇｐ阳性率在初治者及难治者分别为２９．５％及６５．２％，二者比较具有显著性差异（Ｐ＜０．００１）；难治者以Ｐ－ｇｐ高表达为主。不同ＡＭＬ亚型、不同患者Ｐ－ｇｐ表达差异显著，以杂合性白血病表达最高（７５％），Ｍ３表达最低（３．６％）。Ｐ－ｇｐ＋患者的完全缓解（ＣＲ）率为１６．９％，显著低于Ｐ－ｇｐ－者的７６．５％（Ｐ＜０．００１）。Ｐ－ｇｐ＋Ｍ１、Ｍ２、Ｍ５患者的ＣＲ率分别显著低于相应的Ｐ－ｇｐ－者（Ｐ值分别为＜０．００５，＜０．００１及＜０．０５）。提示Ｐ－ｇｐ是成人ＡＭＬ预后差的重要指标
The expression of P-gp in 173 untreated and 23 intractable adult acute myeloid leukemia (AML) cells was detected by indirect immunofluorescence with anti-multidrug resistant P-glycoprotein (P-gp) and flow cytometry. The results showed that the positive rates of P-gp were 29.5% and 65.2% in the untreated and refractory patients, respectively, and there was a significant difference between the two (P<0.001); P-gp was refractory. High expression mainly. The expression of P-gp was significantly different in different AML subtypes and different patients, with the highest expression in heterozygous leukemia (75%) and the lowest expression of M3 (3.6%). The complete remission (CR) rate of P-gp+ patients was 16.9%, which was significantly lower than that of P-gp-76.5% (P<0.001). The CR rates of P-gp+M1, M2, and M5 patients were significantly lower than those of the corresponding P-gp- patients (P values < 0.005, <0.001, and <0.05, respectively). It is suggested that P-gp is an important indicator of poor prognosis of adult AML